Although T-DXd has demonstrated significant efficacy in HER2-overexpressing gynecological malignancies such as cervical, endometrial, and ovarian cancers (23), there are currently no direct research reports on the use of T-DXd for the treatment of cervical mucosal melanoma. This evidence concerns the gene ERBB2 and ovarian carcinoma.